VBL Therapeutics Presents Positive Data on VB-111 in Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer at the ITC 2015 Conference
21 oct. 2015 16h02 HE
|
VBL Therapeutics
TEL AVIV, Israel, Oct. 21, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced positive results from its multi-cohort Phase 2 trial of VB-111 in advanced radioiodine-refractory...
VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
28 sept. 2015 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 28, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced full Phase 2 data on VB-111 in combination with Bevacizumab (Avastin™) in rGBM. Data were...
VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
17 sept. 2015 16h01 HE
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 17, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Trial of VB-111 in Recurrent Glioblastoma
20 août 2015 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 20, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today that the first patient has been dosed in the Company's GLOBE™ Study, a pivotal Phase 3 trial of...
VBL Therapeutics Announces Second Quarter 2015 Financial Results and Provides Business Update
13 août 2015 08h00 HE
|
VBL Therapeutics
-- Reported Strengthened, Statistically Significant Interim Data From VB-111 Phase 2 Study in rGBM --
-- Reported Clinically Meaningful Interim Data From VB-111 Phase 1/2a Study in...
VBL Therapeutics to Report Second Quarter 2015 Financial Results on August 13, 2015
06 août 2015 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 6, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics to Present Data on Proprietary Gene Therapy Vascular Targeting System(TM) and Lead Product VB-111 - at Drug Discovery and Therapy World Congress 2015
14 juil. 2015 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, July 14, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Reports Updated Interim Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
01 juin 2015 07h30 HE
|
VBL Therapeutics
TEL AVIV, Israel, June 1, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Present Phase 1/2a Data From VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
30 mai 2015 14h15 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 30, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Webcast Analyst and Investor Event at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2015
26 mai 2015 08h30 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 26, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...